Back to Search Start Over

Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study

Authors :
Laurent Guilleminault
Claire Camus
Chantal Raherison-Semjen
Audrey Capdepon
Arnaud Bourdin
Philippe Bonniaud
Stéphanie Fry
Gilles Devouassoux
François-Xavier Blanc
Christophe Pison
Clairelyne Dupin
Naji Khayath
Joelle Courdeau
Judith Valcke-Brossollet
Cécilia Nocent-Ejnaini
Fabien Rolland
Carmen Lamandi
Alain Proust
Anaig Ozier
Laurent Portel
Wanda Gaspard
Pauline Roux-Claude
Antoine Beurnier
Stéphanie Martinez
Jean-Marc Dot
Florence Hennegrave
Guillaume Vignal
Etienne Auvray
Nicolas Paleiron
Nicolas Just
Jean Miltgen
Maud Russier
Cécile Olivier
Camille Taillé
Alain Didier
Source :
Therapeutic Advances in Respiratory Disease, Vol 17 (2023)
Publication Year :
2023
Publisher :
SAGE Publishing, 2023.

Abstract

Background: Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with biologics. Purpose: We aim to describe asthma control and healthcare consumption of severe asthma patients treated with biologics. Design: The Second Souffle study is a real-life prospective observational study endorsed by the Clinical Research Initiative in Severe Asthma: a Lever for Innovation & Science Network. Methods: Adults with a confirmed diagnosis of severe asthma for at least 12 months’ duration were enrolled in the study. A self-administered questionnaire including the Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and a compliance evaluation test was given to the patients. Healthcare consumption within 12 months prior to enrolment was documented. In patients receiving biologics, doctors indicated whether the patients were biologic responders or non-responders. Results: The characteristics of 431 patients with severe asthma were analysed. Among them, 409 patients (94.9%) presented asthma with type 2 inflammation (T2 high) profile, and 297 (72.6%) patients with a T2 high phenotype were treated with a biologic. Physicians estimated that 88.2% of patients receiving biologics were responders. However, asthma control was only achieved in 25.3% of those patients (ACQ > 0.75). A high proportion of patients (77.8%) identified as responders to biologics were not controlled according to the ACQ score. About 50% of patients continue to use oral corticosteroids either daily (25.2%) or more than three times a year for at least three consecutive days (25.6%). Gastro-oesophageal Reflux Disease (GERD) and Obstructive Sleep Apnoea syndrome (OSA) were identified as independent factors associated with uncontrolled asthma. Conclusion: Although a high proportion of severe asthma patients respond to biologics, only 25.3% have controlled asthma. GERD and OSA are independent factors of uncontrolled asthma.

Details

Language :
English
ISSN :
17534666 and 63204908
Volume :
17
Database :
Directory of Open Access Journals
Journal :
Therapeutic Advances in Respiratory Disease
Publication Type :
Academic Journal
Accession number :
edsdoj.75b2e5e63204908b0c7dc6bd3893d10
Document Type :
article
Full Text :
https://doi.org/10.1177/17534666231202749